report phase triplerx data phase ii studi
proteostasi report phase triplerx data cftr corrector potenti
amplifi homozyg cf patient show per protocol
benefit vs baselin day
threshold set vertex phase triplerx trial day proteostasi
clear rational plan phase ii studi higher dose triplerx homozyg
heterozyg patient start data around could posit
proteostasi commenc phase trial potenti fda approv
base result compani priorit proprietari triplerx develop
symdeko add-on strategi proteostasi guid cash remain
overweight howev lower price target push
triplerx launch
proj ev less net debt
phase triplerx data proteostasi report phase data homozyg
cf patient cohort evalu
cohort
placebo safeti clean report sae discontinu
per protocol basi triplerx achiev baselin
request cf foundat studi enrol cf patient activ
colon volatil respiratori function predispos rapid pulmonari
declin back patient proteostasi analysi show triplerx
achiev benefit baselin vs placebo
threshold set vertex phase triplerx trial
day patient age note proteostasi triplerx data day
older adult popul importantli
triplerx cohort continu increas day day indic us longer
chlorid decreas baselin vs placebo
day
step pti triplerx believ result warrant evalu
proteostasi intend start phase ii studi first trial
random homozyg patient triplerx
doublet placebo
second trial random heterozyg patient either triplerx
placebo efficaci endpoint
includ sweat chlorid cfq-r could report data around
trial set phase trial start middl next year result
anticip triplerx fda approv launch one year later
cf competit space proteostasi drug may fail clinic gain regulatori
proteostasi develop drug treat cystic fibrosi
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
reiter overweight rate proteostasi howev decreas price target
base lower project enterpris valu million
million due push triplerx launch proteostasi intend
conduct phase ii triplerx studi initi registr phase trial
specif valu proteostasi proprietari triplerx regimen million
appli standard multipl sale million discount back
prior valu triplerx sale million appli multipl
sale million discount back
valu triplerx cf sale europ million appli multipl
sale million discount back prior valu triplerx cf
europ million appli multipl sale million discount back
view lower discount rate appropri phase ii program
continu add net cash million divid project market cap
million million share arriv lower price target pleas see
exhibit
page
thousand except per share
research develop
gener administr
compani report piper jaffray estim
current disclosur inform compani found http //www piperjaffray com/researchdisclosur
